相关实验视频

Updated: Sep 19, 2025

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model

Published on: October 31, 2012

作为治疗囊性纤维化症的系统性子宫内基因编辑

Adele S Ricciardi^1,2, Christina Barone³, Rachael Putman^1,2

¹Department of Biomedical Engineering, Yale University, New Haven, CT 06520.

Proceedings of the National Academy of Sciences of the United States of America

|June 10, 2025

概括

在子宫内基因编辑纠正了出生前多个器官中的囊性纤维化 (CF) 突变. 这种方法对治疗影响发育早期多种组织的遗传性疾病充满希望.

科学领域:

遗传学和基因治疗
发展生物学发展生物学
医学研究医学研究

背景情况:

囊性纤维化 (CF) 是一种由CF跨膜导电性调节器 (CFTR) 基因突变引起的遗传性疾病,导致出生时存在的多器官损伤.
早期干预对于CF至关重要,以防止呼吸道,胃肠道和生殖系统的不可逆转的器官损伤.
在子宫内基因编辑为解决出生前遗传缺陷提供了一个潜在的策略,促进正常的器官发育.

研究的目的:

通过在子宫内基因编辑来证明用于囊性纤维化多器官突变校正的可行性.
评估基因编辑剂在发育中的胎儿中系统输送的疗效和安全性.

主要方法:

使用的核酸被封装在聚合物纳米颗粒中,用于在子宫内进行系统性输送.
在产前发育过程中对患有CF突变的小鼠模型进行基因编辑.
评估产后CFTR基因活性,并选关键组织的非目标突变.

主要成果:

在出生后,在呼吸道和胃肠道组织中达到持续的CFTR活性水平.
确认了成功的多器官突变纠正,在部分同源的位置没有可检测的非目标突变.
通过产前基因编辑证明了通过产前基因编辑显著疾病修改的潜力.

结论:

系统性子宫内基因编辑是一种可行的策略,可以在出生前纠正影响多种组织的单一性疾病.
这种方法有望预防或减轻发育早期的囊性纤维化等遗传疾病的影响.
进一步的研究可以探索这种产前基因编辑技术的长期疗效和安全性.

关键词:

囊性纤维化症是什么基因编辑基因编辑在子宫内,在子宫内.纳米颗粒是一种纳米粒子.系统的交付系统的交付

更多相关视频

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

Intravenous and Intra-amniotic In Utero Transplantation in the Murine Model

Intravenous and Intra-amniotic In Utero Transplantation in the Murine Model

Published on: October 9, 2018

相关概念视频

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Cystic Fibrosis: Pathogenesis

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

CRISPR/Cas9 Genome Editing

CRISPR/Cas9 Genome Editing

The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...

What is Genetic Engineering?

What is Genetic Engineering?